Compare NCNO & PAHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCNO | PAHC |
|---|---|---|
| Founded | 2011 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2022 | 2014 |
| Metric | NCNO | PAHC |
|---|---|---|
| Price | $16.55 | $34.04 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 4 |
| Target Price | $26.07 | ★ $41.25 |
| AVG Volume (30 Days) | ★ 3.3M | 270.7K |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.91% |
| EPS Growth | 115.15 | ★ 1883.33 |
| EPS | 0.12 | ★ 1.90 |
| Revenue | $594,781,000.00 | ★ $833,350,000.00 |
| Revenue This Year | $9.53 | $17.03 |
| Revenue Next Year | $8.97 | $3.82 |
| P/E Ratio | $135.17 | ★ $17.92 |
| Revenue Growth | ★ 10.01 | 4.12 |
| 52 Week Low | $13.80 | $25.58 |
| 52 Week High | $33.92 | $60.08 |
| Indicator | NCNO | PAHC |
|---|---|---|
| Relative Strength Index (RSI) | 48.29 | 54.07 |
| Support Level | $14.04 | $30.55 |
| Resistance Level | $17.22 | $34.67 |
| Average True Range (ATR) | 0.77 | 1.25 |
| MACD | -0.16 | 0.28 |
| Stochastic Oscillator | 17.15 | 79.28 |
Ncino Inc is a provider of cloud-based software for financial institutions. It is focused on developing the nCino Platform to transform commercial and small business lending for community and regional banks in the U.S. With the company's platform financial institutions can Operate More Intelligently, Improve Efficiency, Elevate Employee and Client Experiences, and Manage Risk and Compliance Continuously Rather Than Reactively. It has built and acquired technology, including SimpleNexus, DocFox, FullCircl, ILT, Visible Equity, FinSuite, and Sandbox Banking, to augment the nCino Platform's capabilities for mortgage lending, onboarding, account opening, indirect auto lending, and analytics and AI. The company operates as one operating segment.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.